ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC Annual Review – Straight Talk for Investors

Let’s cut through the noise and see how Enanta Pharmaceuticals really did this year. Imagine we’re chatting over coffee about a biotech friend who’s chasing viruses for a living.

---

1. The Year at a Glance

Enanta develops antiviral drugs, focusing on hepatitis C (which they’re known for), RSV (a severe respiratory virus), and hepatitis B. This year was mixed:

• 🎉 Early wins in new RSV drug trials
• 💥 A late-stage RSV study failed spectacularly
• 💰 Revenue dropped nearly 50% (more on that below)

---

2. Financial Snapshot: The Good and Ugly

• Revenue: $71 million (down from $136 million last year).
  • Why? Their hepatitis C drugs earned fewer royalties – like getting smaller royalty checks from partners.
• Losses: $153 million (worse than last year’s $128 million loss).
• Spending: $135 million on R&D (up slightly).
• Cash Left: $375 million (down from $432 million).

Translation: They’re burning cash, and revenue is shrinking fast. Their savings could last 2-3 years unless something changes.

---

3. Wins vs. Stumbles

✅ Bright Spots:

• Early data suggests their new RSV drug (EPN-104) might work better than existing options.
• Progress in hepatitis B research (a huge unmet need affecting 300 million people).

🚨 Red Flags:

• A late-stage RSV drug (EDP-938) failed key goals – a major setback.
• No new revenue streams to replace declining hepatitis C royalties.

---

4. Survival Watch

• Cash Lifespan: ~2-3 years at current burn rates.
• What’s Next? They’ll likely need to partner with a big pharma company or raise cash (possibly diluting shares) by 2025.

---

5. Big Risks to Know

• Trial Roulette: Their future hinges on RSV and hepatitis B drugs succeeding in trials – high-risk, high-reward.
• RSV Competition: Pfizer and GSK already sell vaccines. Enanta must prove their treatment is better.
• Cash Crunch: If trials fail, they could run out of money fast.

---

6. The Bottom Line for Investors

Consider Enanta only if:

• You’re comfortable with high-risk biotech bets.
• You understand this is a binary play: Success in 2024/25 trials could send shares soaring, but failure could wipe out gains.

Avoid if:

• You prefer stable companies with clear revenue growth.
• You’re uneasy about potential stock dilution or cash crises.

---

Final Takeaway:
Enanta is a "swing for the fences" stock. Their hepatitis C cash cow is fading, and their future depends entirely on unproven drugs. The next 12-18 months will decide whether they become a comeback story or a cautionary tale. Investors should treat this as a speculative play, not a core holding.

Note: Enanta’s annual report provided limited updates beyond these key points, which could signal less transparency for investors.

---

Want to invest? Think of this like betting on a startup – thrilling if it works, painful if it doesn’t. Always keep this to a small part of your portfolio!